Paraza Pharma, Inc

Milestone Pharmaceuticals Inc., based in Montréal, Québec, is focused on developing innovative treatments for patients experiencing acute episodes of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Their investigational product, etripamil, is a novel nasal spray designed for at-home administration, addressing the urgent need for therapies outside the emergency department or hospital setting. Committed to providing cardiac peace of mind, Milestone Pharmaceuticals endeavors to fill existing therapy gaps for various episodic cardiovascular conditions, including angina. The company recognizes the importance of patient and researcher collaboration in advancing medical breakthroughs through clinical trials, offering appreciation to those who contribute to scientific discovery. Generated from the website

Paraza Pharma, Inc. is a fully integrated drug discovery organization based in Saint-Laurent, QC, dedicated to providing innovative and cost-effective solutions for drug discovery and development. With a focus on timely delivery and collaboration, Paraza partners with clients to advance their drug discovery programs through expertise in biology, chemistry, and DMPK services. As a rapidly growing organization, Paraza Pharma fosters a dynamic and collaborative work environment that prioritizes scientific excellence, innovation, and creativity. The company prides itself on its results-oriented approach and commitment to helping partners overcome challenges in drug discovery, measuring its impact by the success of its clients. Generated from the website

BetterLife Pharma Inc. is an emerging biotechnology company based in Dollard-Des Ormeaux, Quebec, dedicated to developing and commercializing patient-friendly therapeutics for neuropsychiatric and neurological disorders. Their innovative approach aims to produce non-hallucinogenic medicines that address a wide range of unmet mental health conditions, including anxiety, depression, and PTSD. The company's lead product, BETR001, is a second-generation LSD derivative designed to mimic the therapeutic properties of LSD without its hallucinogenic side effects. By focusing on evidence-driven solutions, BetterLife Pharma strives to provide effective treatments for debilitating psychiatric disorders and severe neurological conditions, ultimately aiming to enhance the quality of life for patients. Generated from the website